EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs. [electronic resource]
Producer: 20140127Description: 114-27 p. digitalISSN:- 2045-7634
- Animals
- Antibiotics, Antineoplastic -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols
- Cell Proliferation
- Drug Synergism
- ErbB Receptors -- antagonists & inhibitors
- Humans
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mitogen-Activated Protein Kinases -- antagonists & inhibitors
- Molecular Targeted Therapy
- Neoplasm Transplantation
- Neoplasms -- drug therapy
- STAT3 Transcription Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Sirolimus -- administration & dosage
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.